# A Phase 1 Study of PROT-001.

> **NCT06981299** · PHASE1 · COMPLETED · sponsor: **Protego Biopharma Pty Ltd** · enrollment: 102 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PROT-001
- **DRUG:** Rosuvastatin 10mg
- **DRUG:** Digoxin 0.25 mg

## Key facts

- **NCT ID:** NCT06981299
- **Lead sponsor:** Protego Biopharma Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-29
- **Primary completion:** 2025-12-23
- **Final completion:** 2025-12-23
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06981299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06981299, "A Phase 1 Study of PROT-001.". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT06981299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*